Susquehanna International Group’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-8,100
| Closed | -$240K | – | 12500 |
|
|
2022
Q4 | $240K | Sell |
8,100
-10,000
| -55% | -$284K | ﹤0.01% | 9673 |
|
|
2022
Q3 | $431K | Buy |
+18,100
| New | +$417K | ﹤0.01% | 8872 |
|
|
2022
Q2 | – | Sell |
-10,100
| Closed | -$254K | – | 12810 |
|
|
2022
Q1 | $254K | Buy |
+10,100
| New | +$308K | ﹤0.01% | 10676 |
|
|
2021
Q4 | – | Sell |
-6,200
| Closed | -$264K | – | 13057 |
|
|
2021
Q3 | $264K | Buy |
+6,200
| New | +$255K | ﹤0.01% | 10884 |
|
|
2021
Q2 | – | Sell |
-8,000
| Closed | -$326K | – | 12507 |
|
|
2021
Q1 | $326K | Sell |
8,000
-3,500
| -30% | -$133K | ﹤0.01% | 10429 |
|
|
2020
Q4 | $520K | Buy |
+11,500
| New | +$436K | ﹤0.01% | 8200 |
|
|
2020
Q3 | – | Sell |
-9,500
| Closed | -$358K | – | 10497 |
|
|
2020
Q2 | $358K | Sell |
9,500
-39,300
| -81% | -$1.29M | ﹤0.01% | 8025 |
|
|
2020
Q1 | $1.41M | Sell |
48,800
-68,400
| -58% | -$2.77M | ﹤0.01% | 4617 |
|
|
2019
Q4 | $6.08M | Buy |
117,200
+45,000
| +62% | +$2.61M | ﹤0.01% | 2715 |
|
|
2019
Q3 | $3.96M | Buy |
72,200
+57,100
| +378% | +$2.93M | ﹤0.01% | 3050 |
|
|
2019
Q2 | $613K | Sell |
15,100
-40,600
| -73% | -$1.48M | ﹤0.01% | 6838 |
|
|
2019
Q1 | $1.68M | Buy |
55,700
+35,700
| +179% | +$1.22M | ﹤0.01% | 4036 |
|
|
2018
Q4 | $672K | Sell |
20,000
-15,000
| -43% | -$541K | ﹤0.01% | 5440 |
|
|
2018
Q3 | $1.48M | Sell |
35,000
-17,700
| -34% | -$699K | ﹤0.01% | 4512 |
|
|
2018
Q2 | $1.69M | Buy |
52,700
+24,200
| +85% | +$997K | ﹤0.01% | 4319 |
|
|
2018
Q1 | $1.42M | Buy |
+28,500
| New | +$1.61M | ﹤0.01% | 4546 |
|
|
2017
Q4 | – | Sell |
-23,500
| Closed | -$1.36M | – | 9177 |
|
|
2017
Q3 | $1.36M | Buy |
23,500
+4,900
| +26% | +$256K | ﹤0.01% | 4664 |
|
|
2017
Q2 | $918K | Sell |
18,600
-10,000
| -35% | -$461K | ﹤0.01% | 5439 |
|
|
2017
Q1 | $1.24M | Buy |
28,600
+12,400
| +77% | +$592K | ﹤0.01% | 4672 |
|
|
2016
Q4 | $793K | Sell |
16,200
-21,100
| -57% | -$976K | ﹤0.01% | 6011 |
|
|
2016
Q3 | $1.78M | Sell |
37,300
-6,300
| -14% | -$311K | ﹤0.01% | 3749 |
|
|
2016
Q2 | $2.34M | Buy |
43,600
+9,800
| +29% | +$462K | ﹤0.01% | 3313 |
|
|
2016
Q1 | $1.51M | Buy |
33,800
+6,300
| +23% | +$256K | ﹤0.01% | 4283 |
|
|
2015
Q4 | $1.05M | Sell |
27,500
-41,700
| -60% | -$1.6M | ﹤0.01% | 5312 |
|
|
2015
Q3 | $2.2M | Buy |
69,200
+17,400
| +34% | +$607K | ﹤0.01% | 4086 |
|
|
2015
Q2 | $1.71M | Buy |
51,800
+23,500
| +83% | +$838K | ﹤0.01% | 5054 |
|
|
2015
Q1 | $1.17M | Sell |
28,300
-55,100
| -66% | -$2.23M | ﹤0.01% | 5435 |
|
|
2014
Q4 | $3.4M | Sell |
83,400
-35,600
| -30% | -$1.39M | ﹤0.01% | 3520 |
|
|
2014
Q3 | $4.36M | Buy |
119,000
+50,200
| +73% | +$2.17M | ﹤0.01% | 3224 |
|
|
2014
Q2 | $3.19M | Buy |
68,800
+11,600
| +20% | +$516K | ﹤0.01% | 3814 |
|
|
2014
Q1 | $2.35M | Buy |
57,200
+31,900
| +126% | +$1.19M | ﹤0.01% | 4056 |
|
|
2013
Q4 | $965K | Buy |
+25,300
| New | +$781K | ﹤0.01% | 5571 |
|
Other funds holding ANIK
CP
VCM
BFM
CM
Susquehanna International Group's ANIK Position: Q1 2026 in Review
Susquehanna International Group increased its Anika Therapeutics (ANIK) stake by 31% in Q1 2026, buying an estimated $87.5K and bringing the position to 31,751 shares worth $460K. The position accounts for ﹤0.01% of the portfolio, ranked #9888.
Susquehanna International Group first reported a position in ANIK in Q4 2013 and has held it in 34 quarters since. The position peaked at $2.78M in Q3 2019. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.
- Susquehanna International Group held 31,751 shares of Anika Therapeutics worth $460K as of Q1 2026.
- Susquehanna International Group bought 7,541 Anika Therapeutics shares in Q1 2026, an estimated $87.5K.
- Anika Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9888 holding.
- Susquehanna International Group first reported a position in Anika Therapeutics in Q4 2013 and has held it in 34 quarters since.
- Susquehanna International Group's Anika Therapeutics position peaked at $2.78M in Q3 2019.
- 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.